UNSPSC 85533559: Replacement of splenic vein with nonautologous tissue substitute, percutaneous endoscopic approach

This classification denotes the group of activities that yields a surgical intervention or procedure to replacement of splenic vein with nonautologous tissue substitute, percutaneous endoscopic approach. This surgical intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 06R14KZ

UNSPSC 85533559 Replacement of splenic vein with nonautologous tissue substitute, percutaneous endoscopic approach is a Commodity code that does not map meaningfully to recent state and local procurement activity. The code's abstract taxonomy name—a surgical procedure—does not reflect what state and local governments are actually buying under this designation. Recent solicitations posted by state departments, counties, and special-purpose health systems that reference this code instead involve occupational medical surveillance, pharmacy benefit management, temporary health professional staffing, independent medical evaluation services, and surgical benefit carve-out programs for employee health plans. These are administrative health services and benefits management activities, not the specific surgical intervention the code nominally describes. The mismatch suggests either a classification error in the source data or that the code is being used as a catch-all for health services procurement without regard to its precise clinical scope.

The recent opportunities do show activity among diverse issuing bodies—state transportation agencies (Washington State Department of Transportation), county health systems and probation departments (Harris County Juvenile Probation Department, Collier County Board of County Commissioners, County of Santa Clara Health System), cities (City of Phoenix Retirement Office, City of Long Beach)—across Arizona, California, Florida, and Washington between August and October 2026, with response deadlines spanning September through October 2026. However, because none of these opportunities align with the code's stated clinical procedure, the code itself shows little relevant recent purchasing signal for firms targeting its actual scope.